Skip to content

A study for the regulation mechanism of microRNA related to microcirculation disturbance and intervention mechanism of activating blood circulation to dissipate blood stasis prescription by constitution conditioning in non-traumatic osteonecrosis o fthe femoral head

A study for the regulation mechanism of microRNA related to microcirculation disturbance and intervention mechanism of activating blood circulation to dissipate blood stasis prescription by constitution conditioning in non-traumatic osteonecrosis o fthe femoral head

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019192
Enrollment
Unknown
Registered
2018-10-30
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention and treatment of bone and joint diseases by Chinese Medicine

Interventions

Blood stasis NONFH:Drug intervention
Normal-constitution:Drug intervention
Unrelated relationship healthy volunteers:Drug intervention

Sponsors

Gansu Provincial Hospital of Traditional Chinese Medicine Ethics Committee
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with osteonecrosis of the femoral head who meet the diagnostic criteria of Chinese and Western Medicine (including surgery or traditional Chinese Medicine); The treatment person); 2. Aged 18~70 years old; 3. Exclude other serious diseases such as heart, brain and kidney; 4. Willing to accept this research investigator; 5. The retention of experimental specimens was approved by the patients or their families (signed informed consent).

Exclusion criteria

Exclusion criteria: 1. Diagnosed as traumatic osteonecrosis of the femoral head; 2. Pregnant or lactating women, who are allergic or unable to accept this treatment; 3. Rheumatoid arthritis, ankylosing spondylitis, dysplasia of the hip, etc; 4. Combined with severe visceral lesions or other serious metabolic abnormalities and bone tumors; 5. Patients with mental illness and mental retardation; 6. Patients who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
phosphatidylinositol-3-kinase, PI3K;protein kinase B, Akt;phosphatase and tensin homolog deleted on chromosome ten, PTEN;SH2-containing inositol 5-phosphatase 1, SHIP1;VEGF;P2Y12;miR-2;miR-155;

Countries

China

Contacts

Public ContactLi Sheng-hua

Gansu Provincial Hospital of traditional Chinese Medicine

820512343@qq.com+86 18809443621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026